1. Cucinotta, D, Vanelli, M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91: 157–160.
Google Scholar | Medline2. Cimerman, S, Chebabo, A, Cunha, CAD, et al. One year after the arrival of COVID-19 in Latin America: what have we learned in Brazil and other countries? Braz J Infect Dis 2021; 25: 101571.
Google Scholar | Crossref | Medline3. Chertcoff, A, Bauer, J, Silva, BA, et al. Changes on the health care of people with multiple sclerosis from Latin America during the COVID-19 pandemic. Mult Scler Relat Disord 2021; 54: 103120.
Google Scholar | Crossref | Medline4. Alonso, R, Silva, B, Garcea, O, et al. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. Mult Scler Relat Disord 2021; 51: 102886.
Google Scholar | Crossref | Medline5. Tsur, SW, Zaher, EA, Tsur, M, et al. Current immunological and clinical perspective on vaccinations in multiple sclerosis patients: are they safe after all? Int J Mol Sci 2021; 22.
Google Scholar | Medline6. Achiron, A, Dolev, M, Menascu, S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler 2021; 27: 864–870.
Google Scholar | SAGE Journals | ISI7. Learmonth, YC, Motl, RW, Sandroff, BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013; 13: 37.
Google Scholar | Crossref | Medline | ISI8. Lotan, I, Wilf-Yarkoni, A, Friedman, Y, et al. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel. Eur J Neurol 2021; 28: 3742–3748.
Google Scholar | Crossref | Medline9. Logunov, DY, Dolzhikova, IV, Zubkova, OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020; 396: 887–897.
Google Scholar | Crossref | Medline10. Folegatti, PM, Ewer, KJ, Aley, PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467–478.
Google Scholar | Crossref | Medline11. Sadoff, J, Gray, G, Vandebosch, A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N Engl J Med 2021; 384: 2187–2201.
Google Scholar | Crossref | Medline12. Allen-Philbey, K, Stennett, A, Begum, T, et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord 2021; 52: 103028.
Google Scholar | Crossref | Medline13. Xia, S, Duan, K, Zhang, Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020; 324: 951–960.
Google Scholar | Crossref | Medline14. Zhang, Y, Zeng, G, Pan, H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21: 181–192.
Google Scholar | Crossref | Medline15. Etemadifar, M, Sigari, AA, Sedaghat, N, et al. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Hum Vaccin Immunother 2021: 1–3.
Google Scholar16. Baden, LR, El Sahly, HM, Essink, B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384: 403–416.
Google Scholar | Crossref | Medline17. Polack, FP, Thomas, SJ, Kitchin, N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383: 2603–2615.
Google Scholar | Crossref | Medline18. Huttner, A, Eperon, G, Lascano, AM, et al. Risk of MS relapse after yellow fever vaccination: a self-controlled case series. Neurol Neuroimmunol Neuroinflamm 2020; 7.
Google Scholar | Crossref19. Farez, MF, Correale, J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197–1206.
Google Scholar | Crossref | Medline | ISI20. Farez, MF, Correale, J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011; 68: 1267–1271.
Google Scholar | Crossref | Medline21. Boucher, VG, Pelaez, S, Gemme, C, et al. Understanding factors associated with vaccine uptake and vaccine hesitancy in patients with rheumatoid arthritis: a scoping literature review. Clin Rheumatol 2021; 40: 477–489.
Google Scholar | Crossref | Medline22. Colmegna, I, Valerio, V, Boucher, VG, et al. Barriers and facilitators to influenza and pneumococcal vaccine hesitancy in rheumatoid arthritis: a qualitative study. Rheumatology (Oxford) 2021.
Google Scholar | Crossref | Medline23. Sormani, MP, Inglese, M, Schiavetti, I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine 2021: 103581.
Google Scholar | Crossref | Medline24. G, S, L, S, Z, C, et al. Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience. J Neurol 2021.
Google Scholar25. Achiron, A, Mandel, M, Dreyer-Alster, S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 2021; 14: 17562864211012835.
Google Scholar | SAGE Journals | ISI26. Apostolidis, SA, Kakara, M, Painter, MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 2021.
Google Scholar | Crossref | Medline